Targeting Leukocyte Trafficking for the Treatment of Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is a chronic immune‐mediated inflammatory disease of the intestine that includes both Crohn's disease and ulcerative colitis, and afflicts nearly 1 million people throughout North America. As our understanding of IBD pathogenesis grows, several new therapies hav...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2015-01, Vol.97 (1), p.22-28
Main Authors: Arseneau, KO, Cominelli, F
Format: Article
Language:English
Subjects:
Animals
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - therapeutic use
Cell Movement - drug effects
Colitis, Ulcerative - drug therapy
Colitis, Ulcerative - immunology
Colitis, Ulcerative - physiopathology
Crohn Disease - drug therapy
Crohn Disease - immunology
Crohn Disease - physiopathology
Drug Design
Humans
Leukocytes - drug effects
Leukocytes - metabolism
Molecular Targeted Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inflammatory bowel disease (IBD) is a chronic immune‐mediated inflammatory disease of the intestine that includes both Crohn's disease and ulcerative colitis, and afflicts nearly 1 million people throughout North America. As our understanding of IBD pathogenesis grows, several new therapies have been developed that use monoclonal antibodies to specifically target key mediators and biological pathways implicated in IBD immune dysfunction. One important pathway involves leukocyte trafficking and infiltration into the affected intestinal tissues. This review provides a summary of the different therapies that have been developed to inhibit leukocyte trafficking to the inflamed gut, and evaluates the relative safety and efficacy of these novel drugs within the context of existing medical therapies for IBD.
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.6